docetaxel + infliximab

**docetaxel + infliximab** is a combination of two distinct drugs, each with its own mechanism of action. Docetaxel is a semisynthetic taxane chemotherapy agent that disrupts microtubule function, inhibiting cell division and leading to cancer cell death[1][4]. Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), used primarily to treat inflammatory diseases by blocking TNF-α activity[2][5]. The combination has been explored in clinical trials for cancer treatment, but there is no standard approved indication for this specific combination. Pharmacokinetic interactions have been noted, with infliximab potentially increasing the metabolism of docetaxel[1][2].

Other names

docetaxel and infliximabinfliximab and docetaxel